Company Filing History:
Years Active: 2004
Title: John Ridden: Innovator in Targeted Therapeutics
Introduction
John Ridden is a notable inventor based in Kent, GB. He has made significant contributions to the field of targeted therapeutics, particularly in relation to diseases associated with scarring and fibrosis. His innovative work has the potential to impact medical treatments and improve patient outcomes.
Latest Patents
John Ridden holds a patent for an isolated target sequence related to a splice variant of PDE5, referred to as PDE5 1. This invention is crucial as it may be used to identify agents, such as modulators, that are useful in the prevention and treatment of diseases associated with scarring and fibrosis. The identified target sequence can also selectively identify smooth muscle cells, myofibroblasts, and myoepithelial cells in samples of both normal and diseased tissue.
Career Highlights
Ridden is currently employed at Pfizer Corporation, where he continues to advance his research and development efforts. His work at Pfizer allows him to collaborate with leading experts in the field and contribute to groundbreaking medical innovations.
Collaborations
John Ridden has worked alongside notable colleagues, including Dinah Parums and Stephen Charles Phillips. Their combined expertise fosters a collaborative environment that enhances the potential for innovative discoveries.
Conclusion
John Ridden's contributions to the field of targeted therapeutics exemplify the impact of innovative thinking in medicine. His patent on the PDE5 1 target sequence represents a significant advancement in the fight against diseases related to scarring and fibrosis.